Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
about
The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxisRNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivoUrokinase receptor and resistance to targeted anticancer agentsUrokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cellsThe urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motilitySuppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascadeThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingCell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysisDifferential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissuesLRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein traffickingExtracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancerThe very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.uPAR induces expression of transforming growth factor β and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells.uPAR-induced cell adhesion and migration: vitronectin provides the keyCytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblastsDeregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.Low density lipoprotein receptor-related protein (LRP1) regulates Rac1 and RhoA reciprocally to control Schwann cell adhesion and migration.Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion.Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cellsSpecific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerTarget genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpressionOld dogs and new tricks: proteases, inhibitors, and cell migration.Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERKLipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells.A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenRNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
P2860
Q22253459-80F30029-4C22-4A36-83D1-AAC8AB9B6B39Q24539093-E8BE5E4C-5724-4BE0-98CD-73009695A307Q26797385-140A2689-55FB-4AE6-A2F8-A8332B70167DQ28142061-3FB1AC30-E1B0-4591-B29D-F84D4814A548Q28212178-F07B27F0-BF2E-4FFF-A4A6-044646112668Q28218095-FD9CF8C3-7A95-4A97-A9ED-9344AF634AD0Q28257803-E58201F1-C93E-49CA-86AD-2AD82354E40BQ28352841-AED41B9F-EE14-4D5A-A1E7-7F8358C72932Q28366493-1C0C7BBB-6C53-41DB-A559-B7253755FFB8Q28507759-35B8C6C2-C7B6-4E7E-8A29-5FF8D74C3CB1Q30164226-A2C015EB-DD64-42FA-B1CC-2E63C61F2BD2Q30303631-E74A2070-84F4-4875-B893-95B5382EF33CQ30304130-2D373880-0B2E-49C8-9F35-AC07E0089A43Q30307084-E8190A64-9CE7-4DA9-BC86-E40B1FAF3D41Q30311208-D560CF33-2565-42D8-9A28-C873282AC6A5Q30365899-D7439825-DC00-4D4A-BEC0-FB20FD945742Q30442374-5F51CA94-4E54-4975-AF7C-4C4A00098936Q30443804-70202490-ED34-4A51-8E6A-3C3D54AF39DDQ30444144-38BEB2E3-AACB-4A81-8B43-B018F59F5E84Q30491518-15BB11B9-E0B8-48BA-90CC-BA01D3DCCE0EQ31506532-35960357-E95D-4531-BD20-91AA1C5FD4F2Q33556249-D727A6CC-454B-424C-B031-8094F42D6520Q33687878-6FDD6681-F463-49E8-936B-722C07ADA224Q33695003-B40B279D-137F-4472-860C-43C0F4073BACQ33707627-9BC4864E-3FC2-4E6F-9546-2DB7F569D2B2Q33824976-A9CAD510-6EE7-4837-ADF6-085D3F092A17Q33952528-BC350921-8D9F-4706-9344-8F86EF6EFF71Q34073304-21F2CD52-34EC-4F61-8F3F-9F027A9BDD47Q34267846-69BE516E-8203-443A-9E82-52449270AC59Q34410643-9B779255-98BB-4FD9-806D-E7D170031338Q34606581-1B5DA7B6-9971-4182-8BCE-3CB24146241AQ34616412-B4BBC19C-7C8A-493C-96F2-1D57B9C57F30Q34997475-1A3C488F-598E-4ED5-8D17-04B138B661AAQ35004950-C5031042-3508-4BD0-8669-BD7F8A16C5B0Q35098346-96D7CA7D-6203-4BCB-83B2-3F41944467EAQ35167706-463E7787-CBB0-4F21-AEF1-CF2241B1D475Q35213763-C3A15D7B-FEFF-45CF-8DD1-7520F4A1E221Q35813903-A6588199-C5BD-450B-9D0E-25E12B89626DQ36059078-0055A958-121A-45E3-9406-401FA993F7EFQ36676608-DC0A903C-1C66-43B3-BC15-A64D3FEF4189
P2860
Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Binding of urokinase-type plas ...... r increased cellular motility.
@ast
Binding of urokinase-type plas ...... r increased cellular motility.
@en
type
label
Binding of urokinase-type plas ...... r increased cellular motility.
@ast
Binding of urokinase-type plas ...... r increased cellular motility.
@en
prefLabel
Binding of urokinase-type plas ...... r increased cellular motility.
@ast
Binding of urokinase-type plas ...... r increased cellular motility.
@en
P2093
P2860
P356
P1476
Binding of urokinase-type plas ...... r increased cellular motility.
@en
P2093
P2860
P304
P356
10.1074/JBC.273.14.8502
P407
P577
1998-04-01T00:00:00Z